Study of NDV-01 for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new sustained-release chemotherapy (NDV-01) given directly into the bladder for people with non-muscle invasive bladder cancer that hasn't responded to BCG therapy or is at intermediate risk. It compares the new drug to standard chemotherapy to see if it can delay or prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your bladder cancer must be non-muscle invasive (not yet in the muscle layer).
- You must have had at least one BCG treatment that didn't work (BCG-unresponsive) or you have intermediate-risk cancer that came back after treatment.
- You must be willing to have frequent cystoscopies (a camera placed in the bladder) and possibly a TURBT (a procedure to remove abnormal tissue).
- Your cancer must be mostly a type called urothelial carcinoma (transitional cell).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.